Skip to main content
SpringerLink
Log in

Isolation and Analysis of Tumor-Infiltrating Treg

  • Protocol
  • First Online:
Regulatory T-Cells

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2559))

Abstract

Besides their important function in immune homeostasis, autoimmunity, and peripheral tolerance, regulatory T cells (Tregs) also play a crucial role in cancer immune evasion, by assisting tumors to shield from antitumor responses by effector cells. Tregs are recruited to infiltrate tumors and upon finding favourable conditions in the tumor microenvironment, proliferate and suppress effector T cell function thereby promoting tumor escape and growth. In human cancer patients and mouse models, a low ratio of effector T cells to Tregs is a key feature of this immune-suppressive tumor microenvironment and correlates with poor prognosis. This chapter describes protocols for the isolation of tumor-infiltrating lymphocytes (TILs) from solid tumors, their quantification, and phenotyping via flow cytometry to assess the effector T cell:Treg ratio and the expression of relevant markers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 475(7355):226–230

    Article  CAS  Google Scholar 

  2. Ward ST, Li KK, Hepburn E, Weston CJ, Curbishley SM, Reynolds GM, Hejmadi RK, Bicknell R, Eksteen B, Ismail T, Rot A, Adams DH (2015) The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer. Br J Cancer 112(2):319–328

    Article  CAS  Google Scholar 

  3. Halvorsen EC, Hamilton MJ, Young A, Wadsworth BJ, LePard NE, Lee HN, Firmino N, Collier JL, Bennewith KL (2016) Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs. Onco Targets Ther 5(6):e1150398

    CAS  Google Scholar 

  4. Phillips JD, Knab LM, Blatner NR, Haghi L, DeCamp MM, Meyerson SL, Heiferman MJ, Heiferman JR, Gounari F, Bentrem DJ, Khazaie K (2015) Preferential expansion of pro-inflammatory Tregs in human non-small cell lung cancer. Cancer Immunol Immunother 64(9):1185–1191

    Article  CAS  PubMed Central  Google Scholar 

  5. Sainz-Perez A, Lim A, Lemercier B, Leclerc C (2012) The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 72(14):3557–3569

    Article  CAS  Google Scholar 

  6. Darrasse-Jeze G, Bergot AS, Durgeau A, Billiard F, Salomon BL, Cohen JL, Bellier B, Podsypanina K, Klatzmann D (2009) Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice. J Clin Investig 119:2648–2662

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Liu C, Workman CJ, Vignali DAA (2016) Targeting regulatory T cells in tumors. FEBS J 283(14):2731–2748

    Article  CAS  Google Scholar 

  8. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759–777

    CAS  PubMed  Google Scholar 

  9. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949

    Article  CAS  Google Scholar 

  10. Shang B, Liu Y, Jiang SJ, Liu Y (2015) Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep 5:15179

    Article  CAS  PubMed Central  Google Scholar 

  11. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005–3010

    Article  CAS  PubMed Central  Google Scholar 

  12. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116:1935–1945

    Article  CAS  PubMed Central  Google Scholar 

  13. Watson MJ, Vignali PDA, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, Menk AV, Rittenhouse NL, DePeaux K, Whetstone RD, Vignali DAA, Hand TW, Poholek AC, Morrison BM, Rothstein JD, Wendell SG, Delgoffe GM (2021) Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 591:645–651

    Article  CAS  PubMed Central  Google Scholar 

  14. Pommier A, Audemard A, Durand A, Lengagne R, Delpoux A, Martin B, Douguet L, Le Campion A, Kato M, Avril MF, Auffray C, Lucas B, Prévost-Blondel A (2013) Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4 + T cells. Proc Natl Acad Sci USA 110:13085–13090

    Article  CAS  PubMed Central  Google Scholar 

  15. Fujimura T, Ring S, Umansky V, Mahnke K, Enk AH (2012) Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas. J Invest Dermatol 132:1239–1246

    Article  CAS  Google Scholar 

  16. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS (2007) CD4 + CD25 + Foxp3 + regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 104:19446–19451

    Article  CAS  PubMed Central  Google Scholar 

  17. Elpek KG, Lacelle C, Singh NP, Yolcu ES, Shirwan H (2007) CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 178:6840–6848

    Article  CAS  Google Scholar 

  18. Golgher D, Jones E, Powrie F, Elliott T, Gallimore A (2002) Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol 32:3267–3275

    Article  CAS  Google Scholar 

  19. Halvorsen EC, Mahmoud SM, Bennewith KL (2014) Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Rev 33(4):1025–1041

    Article  CAS  Google Scholar 

  20. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210:1695–1710

    Article  CAS  PubMed Central  Google Scholar 

  21. Arce Vargas F, AJS F, Solomon I, Joshi K, Mekkaoui L, Lesko MH, Miranda Rota E, Dahan R, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O’Brien T, Nicol D, Challacombe B, Beers SA, Melanoma TRACERx Consortium, Renal TRACERx Consortium, Lung TRACERx Consortium, Turajlic S, Gore M, Larkin J, Swanton C, Chester KA, Pule M, Ravetch JV, Marafioti T, Peggs KS, Quezada SA (2017) Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors. Immunity 46(4):577–586

    Article  CAS  PubMed Central  Google Scholar 

  22. Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C, Henry JY, Spain L, Ben Aissa A, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Nicol D, O’Brien T, Georgiou A, Sledzinska A, Ben Aissa A, Franz D, Werner Sunderland M, Wong YNS, Henry JY, O’Brien T, Mårtensson L, Ljungars A, Teige I, Frendéus B, TRACERx Melanoma, TRACERx Renal, TRACERx Lung consortia, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Peggs KS, Quezada SA (2018) Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 33(4):649–663. e4

    Article  CAS  PubMed Central  Google Scholar 

  23. Wang R, Wan Q, Kozhaya L, Fujii H, Unutmaz D (2008) Identification of a regulatory T cell specific cell surface molecule that mediates suppressive signals and induces Foxp3 expression. PLoS One 3(7):e2705

    Article  PubMed Central  Google Scholar 

  24. Rodríguez-Perea AL, Arcia ED, Rueda CM, Velilla PA (2016) Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol 185(3):281–291

    Article  PubMed Central  Google Scholar 

  25. Yano H, Andrews LP, Workman CJ, Vignali DAA (2019) Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. Immunology 157(3):232–247

    Article  CAS  PubMed Central  Google Scholar 

  26. Freeman ZT, Nirschl TR, Hovelson DH, Johnston RJ, Engelhardt JJ, Selby MJ, Kochel CM, Lan RY, Zhai J, Ghasemzadeh A, Gupta A, Skaist AM, Wheelan SJ, Jiang H, Pearson AT, Snyder LA, Korman AJ, Tomlins SA, Yegnasubramanian S, Drake CG (2020) A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target. J Clin Invest 130(3):1405–1416

    Article  CAS  PubMed Central  Google Scholar 

  27. Li C, Jiang P, Wei S, Xu X, Wang J (2020) Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer 19:116

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL Cancer Institute, Research Department of Haematology, Cancer Immunology Unit, London, UK

    Katharina Bergerhoff

  2. Institute of Cancer Research, Targeted Therapy Team, London, UK

    Katharina Bergerhoff & Malin Pedersen

  3. Quell Therapeutics, London, UK

    Katharina Bergerhoff

Authors
  1. Katharina Bergerhoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malin Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Imperial College London, London, UK

    Masahiro Ono

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Bergerhoff, K., Pedersen, M. (2023). Isolation and Analysis of Tumor-Infiltrating Treg. In: Ono, M. (eds) Regulatory T-Cells. Methods in Molecular Biology, vol 2559. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2647-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-2647-4_5

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-2646-7

  • Online ISBN: 978-1-0716-2647-4

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation